$14.75
Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy?
Overview
52-week range
$7.48
$19
66% of range
Avg surprise (last 3)
-10.8%
Avg reaction (last 2)
+3.4%
100% positive
Latest IV / EM
76%
EM ±17.3% · $15 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 4, 2026 | Mar/2026 | $-0.88 | $-0.86 | -2.3% | +59.5% | +5.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.64 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-1.94 | $-1.94 | 0.0% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-2.17 | $-1.67 | -29.9% | — | +1.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.70 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-3.64 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-2.20 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.50 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.32 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.77 | -$1.94 | +60.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-130M | — | $-169M | $-212M | $-222M | — | $-178M | $-334M |
| Net income | $-131M | — | $-173M | $-198M | $-222M | — | $-160M | $-320M |
| EPS (diluted) | $-0.88 | — | $-1.64 | $-1.94 | $-2.17 | — | $-1.70 | $-3.64 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $273M | $230M | $185M | $166M | $98M | $99M | $84M | $239M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $386M | $368M | $324M | $475M | $383M | $538M | $440M | $511M |
| Total assets | $466M | $451M | $409M | $550M | $459M | $615M | $511M | $583M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $337M | $399M | $426M | $416M | $199M | $192M | $195M | $199M |
| Total equity | $130M | $52M | $-17M | $135M | $259M | $423M | $316M | $384M |